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Genomics researchers and policy makers have accused nutrigenetic testing companiesdwhich provide
DNA-based nutritional advice onlinedof misleading the public. The UK and USA regulation of the tests
has hinged on whether they are classed as “medical” devices, and alternative regulatory categories for
“lifestyle” and less-serious genetic tests have been proposed. This article presents the ﬁndings of
a qualitative thematic analysis of the webpages of nine nutrigenetic testing companies. We argue that the
companies, mirroring and negotiating the regulatory debates, were creating a new social space for
products between medicine and consumer culture. This space was articulated through three themes: (i)
how “genes” and tests were framed, (ii) how the individual was imagined vis a vis health information,
and (iii) the advice and treatments offered. The themes mapped onto four frames or models for genetic
testing: (i) clinical genetics, (ii) medicine, (iii) intermediate, and (iv) lifestyle. We suggest that the
genomics researchers and policy makers appeared to perform what Gieryn (Gieryn, T.F. (1983).
Boundary-work and the demarcation of science from non-science: strains and interests in professional
ideologies of scientists. American Sociological Review, 48, 781e795.) has termed “boundary work”, i.e., to
delegitimize the tests as outside proper medicine and science. Yet, they legitimated them, though in
a different way, by deﬁning them as lifestyle, and we contend that the transformation of the boundaries
of science into a creation of such hybrid or compromise categories is symptomatic of current historical
times. Social scientists studying medicine have referred to the emergence of “lifestyle” products. This
article contributes to this literature by examining the historical, regulatory and marketing processes
through which certain goods and services become deﬁned this way.
 2009 Elsevier Ltd. Open access under CC BY license. Introduction
Genetic testing has traditionally been managed by clinical
geneticists concerned with rare and often incurable disorders, such
as Huntington’s disease, caused by a single gene. The test results
have informed sensitive reproductive decisions, which might be
facilitated by specialist counselling.
The recent major public, private and charitable investment in
genomic researchdincluding vast projects, such as the Human
Genome Project and the UK Biobankdhas been justiﬁed by theTrust, Biomedical Ethics Pro-
am members Professor Steve
nd the editors and reviewers
o).
Y license.  promise that genetic tests will beneﬁt the population at large. Both
UK (Department of Health, 2003) and USA (Khoury, 2003)
government agencies have envisioned that soon primary care
clinicians will offer most people genetic tests for susceptibilities for
common diseases together with preventive advice and treatments.
A number of small biotech companies have gone further and
sold genetic tests e such as paternity and ancestry tests, tests for
susceptibilities for illness or addiction or whole genome scans e
online. In this article, we focus on a subset of these companies,
which offer nutrigenetic tests, i.e., a service whereby customers
send DNA samples (mouth swab) and receive, often via mail, advice
on diets and supplements based on testing of a few gene variants.
Following the sociology of technology literature (Pinch & Bijker,
1989), we examine nutrigenetic tests as a technological artifact in
the making or before it becomes taken-for-granted or fails. Exam-
ining such emergent technologies highlights how they are shaped
by diverse social actors. We are especially interested in how
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marketing and sales portals. Yet, the online marketing only makes
sense against the background of the wider network of actors
interested in the technology.
There were only a handful of nutrigenetic testing companies in
2008, but they had attracted considerable public attention. The
media had often more or less advertised the companies, an
example being the 2007 ITV (a UK independent television channel)
programme The Killer in Me, which featured four celebrities taking
a test offered by Genetic Health and claimed to “open awindow not
just on their lives but potentially their deaths” (The Killer in Me,
2007; on the industry bias in media coverage of nutrigenetics see
Caulﬁeld, Shelley, Bubela, & Minaker, 2009).
But nutrigenetic testing companies have also attracted negative
attention. The critics of the companies have included non-
governmental organisations, such as the UK GeneWatch, but most
of the disapproval has come from individuals and institutions
involved in genomics research and policy. Much of the contention
has focused on the scientiﬁc validity of the tests, with critics
accusing the companies in popular, scholarly and regulatory forums
of selling “snake oils” (Pollack, 2006). GeneWatch questioned the
principle of providing dietary advice based on genetic tests, stating
in its parliamentary brieﬁng soon after Sciona started marketing its
nutrigenetic test in the UK that “genes are poor predictors of
complex diseases” (GeneWatch, 2002). Most critics were more
circumspect. Dr. Muin Khoury and colleagues from the U.S. Ofﬁce
for Genomics and Disease Prevention, Centers for Disease Control,
which was in charge of developing ways to use genomic research to
prevent disease, stated in the prestigious journal Nature Genetics
that the science of using genetics to enhance healthy lifestyle
“holds great promise” but was “not ready for prime time” (Haga,
Khoury, & Burke, 2003: 350). Similarly, in 2006 investigators from
the U.S. Government Accountability Ofﬁce (GAO) bought a series of
nutrigenetic tests and accused them of making “medically
unproven” and “meaningless” predictions, whilst hedging their
critiques with statements on how “genetic testing is becoming an
integral part of healthcare with great potential for future test
development and use” (GAO, 2006).
Overall, the debate on nutrigenetic testing resembled what
Gieryn has termed “boundary work”, i.e., “ideological efforts by
scientists to distinguish their work from non-scientiﬁc intellectual
activities” (Gieryn, 1983: 782). In the case of nutrigenetic testing
scientists and functionaries, frequently associated with genomics
research and/or policy, sought to distinguish responsible and
promising future genomic science and medicine from irresponsible
nutrigenetic companies, who had launched the technology
prematurely. However, due to many critics’ vested interest in
genomic research and policy they contradictorily buttressed the
promise of the technology whilst deriding nutrigenetic tests. Only
GeneWatch questioned the principle of using genetic tests as
a basis for preventing common diseases.
The question of what should be done about nutrigenetic tests
also became muddled in the regulatory realm. Nutrigenetic testing
companies had been able to sell their products due to a loophole in
regulation, which did not require “home brew” laboratory tests to
undergo review by Food and Drug Administration (FDA). In 2006 in
hearings in front of Senate’s Special Committee on Aging, following
the damning GAO report, the issue became whether nutrigenetic
tests were medical devices, and if so, which risk classiﬁcation they
should belong to. As stated by Dr. Steve Gutman from FDA during
the hearings:
A product is a medical device if it is intended for diagnosis of
disease or other conditions, or for use in the cure, mitigation,
treatment, or prevention of disease. To the extent the tests GAOinvestigated make such claims; they are devices subject to FDA
jurisdiction (Gutman, 2006: 2).
In response Rosalynn Gill-Garrison, Sciona’s Chief Technology
Ofﬁce testiﬁed in the same hearings that the company’s services
were not, indeed, medical but offered:
. genetic information to consumers concerning their nutri-
tional wellbeing, contributing to their health and wellness.
Sciona is not involved in diagnostic or disease-related services
or information (Gill-Garrison, 2006).
In the UK, the regulation of genetic tests was governed by the
European Union’s In Vitro Diagnostic Devices (IVDD) Directive,
which was implemented nationally by the Medicines and Health-
care Products Regulatory Agency (MHRA). Similar to the USA situ-
ation, the regulation hinged on the question of whether
nutrigenetic tests would fall under the ambit of the IVDD Directive
as “devices used for medical purposes,” and if so how their risk
would be classiﬁed. The Human Genetics Commission (HGC) e an
advisory body consisting of individuals with a genetics interest,
such as clinical geneticists, genetic counselors, scientists, patient
and industry representatives and members of public, such as
science journalists e had been pushing for the regulation of direct-
to-consumer (DTC) genetic testing since 2003 (HGC, 2003). In its
2007 report on DTC-testing, HGC noted that MHRA had notiﬁed
them that “so called ‘lifestyle’ tests” do not fall under their remit
(HGC, 2007: 16). The commission reported that it had considered
recommending that all genetic tests should be regulated in the
same manner but had concluded it would be “a mistake.” Rather, it
ended up recommending that.
. an alternative regulatory mechanism be created to tests, such
as ‘lifestyle’ tests, which are currently not regulated as they fall
outside the scope of the IVDD directive (HGC, 2007: 16).
Due to legal technicalities and the prevailing view among the
genomics community that not all genetic tests were alike (i.e.
“new” genetic susceptibility tests were qualitatively different from
the old single gene clinical genetic tests, e.g., Khoury, 2003), the
regulatory debates were creating a new regulatory and marketing
category for non-medical or “lifestyle” genetic tests. Further, even if
the tests would be classiﬁed as medical, in the EU genetic tests
would be considered low risk, and if this was to be the case in the
USA they would not require FDA premarket review. Within this
emergent framework, nutrigenetic tests were falling into possibly
several categories between medical and consumer products, such
as lifestyle or low-risk medicine, and be expected to fulﬁll some, yet
to be speciﬁed, criteria.
As stated by an industry representative during pilot ﬁeldwork in
2006, in this situation the companies needed to choose a strategy
between developing products more akin to “diet drinks and skin
creams,”which customers donot necessarily expect towork, ormore
serious “cardiovascular products,”whichwould need to be backed up
by more extensive research. Different companies were choosing
slightly different strategies. For example, an industry representative
stated that nutrigenetic tests “should” be classed as medical devices
and regulated in a similar manner to disease risk and pharmacoge-
netic tests. However, the representative acknowledged that.
. therewould be industry pressure to separate [nutrigenetics], to
allow companies that are not going to specialise in the areawe’re
doing to be a bit freer with their you know, eat lots of broccoli and
take some of our own homemade pills type thing (Interviewwith
an anonymous industry representative (P26) in June 2008).
In this statement, the industry representative was also doing
boundary work (Gieryn, 1983) in an attempt to distinguish his
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medical devices, and companies selling lifestyle genetic tests and
“homemade pills.” The statement also illustrates how different
companies were pitching their products to slightly different
marketing and regulatory niches between lifestyle and light-
medicine.
In this article, we will analyse the webpages of nutrigenetic
testing companies as a case study of the production of a new
marketing and regulatory category between medicine and
consumer culture. We will also pay attention to how different
companies shape the category differently.
Biomedicalisation and consumerization
The undertakings of the nutrigenetic testing companies may be
fascinating per se, but we were interested in them because they
were symptomatic of broader transformation in medicine. They
also highlighted a few rarely discussed or conceptualised features
in this transformation.
As already discussed, the efforts of representatives of public
policy and genomic research to construct a boundary (Gieryn,1983)
between proper science and medicine and nutrigenetic testing in
the popular, scholarly and regulatory realms were not entirely
successful. Gieryn’s work has frequently been used by social
scientists to make sense of the strategic actions of scientists to
exclude others in, for example, stem cell research (Wainwright,
Williams, Michael, Farsides, & Cribb, 2006). There is a paucity of
studies on cases where boundary work has faltered. Further, many
of Gieryn’s (1999) case studies focus on the 19th century when
science and medicine were delineating their autonomous profes-
sional spheres of expertise against competing authorities, such as
organized religion and industrialists. It has been argued that the
boundaries between science/medicine and varied industry,
government and lay interests have recently blurred (e.g. Nowotny,
Scott, & Gibbons, 2001). This development is likely to render
boundary work increasingly tenuous. We contend that the trans-
formation of defending boundaries of science into a creation of
hybrid or compromise categories, such as lifestyle genetic testing, is
symptomatic of current historical times. It also remains a poorly
researched area.
Medical sociologists have made sense of current, historical
transformations in medicine with terms such as biomedicalisation
(Clarke, Shim, Mamo, Fosket, & Fishman, 2003) and information-
based medicine (Nettleton, 2004). Clarke et al. (2003) argue that
biomedicalisation is characterised by increasing privatisation and
commodiﬁcation of medical research and services, which expands
biomedical jurisdiction into ever new areas of life. Studies on
processes of (bio)medicalisation have focused, for example, on how
phenomena such as shyness, sadness (Conrad & Leiter, 2004) or
impotence (Fishman, 2004) are attributed a biological/molecular
cause (also Rose, 2007), assigned a diagnostic label (social anxiety
disorder, depression, sexual dysfunction) and a concomitant phar-
maceutical product (Paxil, Prozac, Viagra).
Nutrigenetic testing is similar to these cases in that it bio-
medicalises an everyday phenomenon e eating e by associating it
with a molecular underpinning and speciﬁc diets or dietary prod-
ucts. The contribution of our nutrigenetics case study to this liter-
ature is that it highlights how biomedicalisation and attendant
privatisation and commodiﬁcation happened through the creation
of a new marketing and regulatory space for “lifestyle” products
between medicine and consumer culture. Gieryn’s (1983, 1999)
notion of boundary work helps to make sense of the historical
speciﬁcity of this development. Even if the media and regulatory
debates appeared as boundary work, they did not delegitimize
nutrigenetic tests as outside science/medicine, as happened to, forexample, phrenology or composting in Gieryn’s (1999) historical
cases. Rather, the debates created new rules that legitimated the
tests on slightly different grounds.
The casual use of the term “lifestyle” or “enhancement” in
relation to nutrigenetic tests is common not only in regulatory texts
but also in social science research literature (e.g. Geransar &
Einsiedel, 2008; Martin & Frost, 2003) and is also used, for
example, to describe Viagra (Fishman, 2004; Fox, Ward, & ÓRourke,
2005) and over-the-counter cholesterol lowering statins in the UK
(Edgley, 2007). However, these works use the label in a descriptive
manner; they do not examine how its recurrence across scholarly,
regulatory, media and everyday realms creates a new social space
for such products. This is what we will investigate.
Methods
To explore how nutrigenetic testing companies were shaping
the technology amidst regulatory and public debates, we analysed
their webpages, onwhich theymarketed and often directly sold the
tests. We analysed the webpages of all companies marketing
nutrigenetic tests on the Internet in 2007 and 2008. The sample is
complete to the best of our knowledge, given the difﬁculty of
tracking down frequently changing websites. The companies ana-
lysed were: Genelex (USA), Genovations/Genova Diagnostics (USA),
Genetic Health (UK), Interleukin Genetics/Quixtar (USA), Market
America (USA), Nutrigen (USA), Salugen (USA), Sciona (USA,
formerly UK), and Suracell (USA).
The forces behind nutrigenetic testing companies included
scientists; for example, one of the managers of Genetic Health,
Dr. Paul Jenkins was a Reader in endocrinological oncology at the
University of London. Many of the companies had complex
connections with the consumer industry. The largest investor in
Sciona was DSM, specialising in nutrition, pharmaceuticals,
plastics and chemical products (DSM, 2006). Nutrigenetic testing
companies also sold consumer products, which accounted for the
main source of revenue for Interleukin Genetics (Interleukin
Genetics, 2008), which had a commercial partnership with the
consumer company Alticor/Amway, proprietor of brands, such as
Nutrilite. Many companies did not sell their own tests. Genelex
and Market America distributed Sciona’s test under a different
name. Genelex marketed a number of other DNA tests, Market
America sold a range of consumer products from supplements to
garden furniture; between 2006 and 2008 Sciona also sold its
tests through varied and changing intermediaries, such as gro-
cerystores and holistic pharmacies. The UK Genetic Health sold
the test by the Austrian company Genosense. Overall, this
complex alliance of science and consumer, pharmaceutical, retail
and wellness/alternative medicine industry was well poised for
navigating the regulatory and marketing landscape for lifestyle
products.
To provide an overview of the products sold by the nutrigenetic
testing companies, we have described in Table 1 what tests and
associated products they sold and how they purported to deliver
them. In analyzing the webpages, we only focused on marketing
material for nutrigenetic tests and associated products (supple-
ments) and tests (cardiovascular tests), not unrelated tests (pater-
nity testing) or consumer goods.
The webpages of the companies were multimodal (Lemke,
2002) and hypertextual or intertextual. This means that they
combined textual material with visuals (images, layout etc.) and
provided their audiences also with links, which directed visitors to
press coverage of the company, to scientiﬁc articles as well as
company responses to public criticism of their services. The web-
pages, thus, were targeted not only at customers but also at
investors, distributors, scientists, regulators and public media.
Table 1
The model of service delivery, genetic tests and associated treatments offered by the nine online nutrigenetic testing companies analysed in 2008.
Company Delivery Genetic tests Treatments
Genelexa http://www.genelex.com Direct online
Pre-test consultation with
a “DNA Testing Consultant”
Nutritional genetic panel
(Paternity, Ancestry, Drug reaction,
Predictive)
Dietary advice
Vitamin supplements
Genova Diagnostics/Genovations
http://www.genovadiagnostics.com
Ordered through a physician
or nutrition counsellor
‘CardioGenomicPlus’
‘OsteoGenomic’
‘EstroGenomic’
‘DetoxiGenomic’
‘ImmunoGenomic’
‘NeuroGenomic’
Follow-up tests
Dietary and medication advice
Genetic Health
http://www.genetic-health.co.uk
Ordered via a telephone consultation
with counsellor or other company
staff member
Post-test consultation with
a doctor by phone or face-to-face
‘Nutrition Gene’
‘Obesity, diabetes and weight loss’
(Premium Male, Premium Female,
PharmacoGene)
Dietary advice
Follow-up tests
Interleukin Genetics/Quixtar
http://www.ilgenetics.com
Direct online ‘Gensona General Nutrition Genetic Test’
‘Gensona Heart Health Genetic Test’
Dietary advice
Special Nutrilite Heart Health Dietary
Supplement
Developing pharmaceutical,
and nutritional products
Market Americaa
http://www.marketamerica.com
Direct online Gene SNP DNA analysis Gene SNP custom genetic nutritional
formula
Nutrigena http://www.1-888-nutrigen.com Direct online?
With a pre or post consultation with
a “medical expert”
With a consultation on
“Carb cycling diet”
‘Comprehensive’
‘Bone Health’
‘Heart Health’
‘Insulin Resistance’ ‘Inﬂammation’
‘Antioxidant/Detoxiﬁcation’
Dietary advice
Supplement advice
Carb Cycling Diet
Salugen http://www.salugen.com Spas and wellness centers
(phone number offered)
‘GenoTrim Test’
‘SpaGen Test’
Special supplements GenoTrim
weight management regimen
SpaGen nutrition regimen
Scionaa http://www.sciona.com Direct online
Through special pharmacies
and intermediaries
‘MyCellf (The Science of You)’
‘MyCellf (DNA Fitness)’
Dietary advice
Supplement advice
Exercise advice
Suracell
http://www.suracell.com
Direct online (with possible phone
consultation)
Medispas
Physician’s Ofﬁces
Wellness Centers
‘Personal DNA Analysis’ Nutraceuticals: Bone and Joint Health
Blood Sugar and Body Fat Control
Heart and Vascular Health
Detoxiﬁcation and free radical control
Optimal cell function
a Indicates the company was no longer offering nutrigenetic tests in 2009.
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Three authors (PS, MR, NB) read the material and made note of
frequent themes and images. We followed the principle of constant
comparative method (Glaser, 1965), which seeks to inductively
identify recurrent themes in the material. After developing
a preliminary coding scheme all the texts on the current webpages
were downloaded into NVivo 7.0 qualitative software and coded by
MR and PS in 2007 with further revisions to the pages added and
coded by SH in spring 2008. We also took notes of visuals in
conjunction with the texts on the webpages and analysed them
informed by constant comparison (see Clarke, 2005).
We then undertook further analysis of how different companies
gave the themes slightly different spins, clustering into a few
“frames,” following Goffman’s (1974/1986) classic work and its
application to media analysis (Gamson & Modigliani, 1989). Frames
structure experience or suggest “what is at issue” (Gamson &
Modigliani, 1989: 3); they are produced by strategic actions of
individuals and groups, but in order to be successful they have to
resonate with contemporary social sensibilities, and they are often
produced through subtle clues that suggest the meaning of the
issue, for example, whether it is serious or humorous, i.e., a ﬁght or
a play-ﬁght (Goffman, 1974/1986: 41e44). In media, texts frames
are produced through depictions, catchphrases or catchwords and
visual images (Gamson & Modigliani, 1989: 3), and we analysed
how the frames in our material operated through these devices.Results
Main themes
Three prominent themes emerged from the analysis of the
companies’ websites: (i) the nature of genes and the tests, (ii)
the role of the individual vis a vis genetic information, and (iii) the
advice and treatments offered. The companies articulated the three
themes slightly differently, framing their products as “lifestyle,”
“medicine,” or in-between the two (“intermediate”). Based on this
observation, and our knowledge of the controversies around the
tests, we constructed a stratiﬁed classiﬁcation scheme for genetic
testsdranging from clinical genetics through to lifestyle genet-
icsdwhich was taking shape on the webpages and in the debates.
We located the companies’ services and promotional strategies
within this scheme (see Table 2). In what follows, we will analyse
how these frames were articulated on the webpages.
Genes, illness and wellness
On their webpages, many nutrigenetic testing companies
explicitly distanced their services from clinical genetic testing:
Can you tell me if I carry the genes for a serious illness?
No. The Gene SNP DNA Screening Analysis is not a test for
inherited disorders or inherited predisposition to disease.We do
Table 2
Emerging frames or models for genetic testing.
Lifestyle Intermediate Medicine ClinicalGenetics
Individual vis a 
vis health 
information 
Self-health 
optimizing 
online
consumer  
Customers and 
medispas, 
pharmacies, 
dieticians and 
other “experts” 
Physicians and 
patients 
Genetic counsellor 
and counsellee 
Nature of genes 
and tests 
Genetic
variants
guiding
optimization of 
wellness
Genetic
variants
indicating
susceptibility
for disease 
Genetic
variants
predisposing
for disease 
Single gene caused 
disorders or 
predispositions
Advice and 
treatments 
offered
“Natural”
diets, exercise,  
smoking 
cessation
Quasi-drug
formulas, 
nutraceuticals,
supplements, 
over-the- 
counter drugs 
Prophylactic
treatments and 
drugs (e.g. 
statins)
Reproductive
decision making 
Prophylactic
treatments (e.g. 
mastectomy) 
Online
nutrigenetic
testing
companies 
Sciona
     Genelex 
      Market America 
                      Salugen 
                      Suracell 
                      Nutrigen 
                                  Genovations 
                                   Interleukin 
                                   Genetics 
                                                 Genetic 
                                                 Health 
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as Huntington’s disease, cystic ﬁbrosis or sickle cell anemia.
(Market America, 2008, FAQs).
Through such statements, the nutrigenetic testing companies
distinguished their services from clinical genetic tests for disorders
“caused” by a “single gene” and perceived to be riddled with ethical
conundrums. In so doing, they mobilized the distinction frequently
underlined in genomics research (Khoury, 2003) and regulation
(HGC, 2002: 52e54) e paving the way for introducing genetic
testing into everyday healthcare e between “serious” single gene
tests and susceptibility tests with “intermediate” or “low” “impact”
(HGC, 2002). The nutrigenetic tests were thus framed as “less
serious” than clinical genetic ones, suggesting they were to be
consumed and regulated more lightheartedly or liberally.
When it came to deﬁning the exact nature of the nutrigenetic
tests, the companies had carefully crafted slightly different
descriptions. Some companies (especially Sciona and itsdistributors Genelex and Market America) went to great lengths to
avoid associations between their services and diagnosis or predic-
tion of disease:
Optimize the health of your skin and bones; heart and mind by
optimizing your personal diet and supplement intake. Genetic
testing combined with a lifestyle assessment, provide you with
a scientiﬁcally based, personal blueprint for optimizing health
(Genelex, 2008, nutrigenetic test home).
The choice of the catchphrase, “optimize health,” reﬂected the
regulatory debates, discussed previously, seeking to frame the tests
as not “medical devices” but lifestyle. Further, the references to
“health of your skin and bones,” did not bring into mind avoiding
illness but enhancing beauty and ﬁtness or strength. The combi-
nation of words “heart and mind” in relation to health does not
immediately evoke the physical organ heart but ambiguous mental
and physical wellbeing. One only needs to imagine how different
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“cardiovascular disease,” were used. This illustrates how the “life-
style” framewas created not just by avoiding disease-related claims
with legal consequences but through consistent clues that sug-
gested the tests were not serious medical devices but ambivalent
wellness products (see Goffman, 1974/1986: 41e44).
Some companies, such as Salugen, combined catchwords asso-
ciated with medicine and those associated with lifestyle or
consumer culture, which is why we have termed their framing
“intermediate.” Often times the catchphrases producing the inter-
mediate frame were contradictory or even odd. An example is
Salugen’s description of the “timeline” of genetics innovations from
Gregory Mendel and Watson and Crick until the initiation of the
Human Genome Project in 1986 and.
2005dSalugen pioneers nutritional gene therapy by analyzing
a person’s DNA to customize their nutritional supplement pill
ingredients (Salugen, innovations timeline, 2008, emphasis in
the original).
The italicized catchword here is inherently contradictory. The
word “nutrional” referred to nutrients and eating, i.e., lifestyle or
consumer culture. “Gene therapy” generally refers to a distinctly
serious and experimental technology of modifying “defective
genes” into healthy ones and has been, largely unsuccessfully, used
to treat life-threatening conditions, such as forms of human
immunodeﬁciency. Combining these words created a confusion as
well as suggested that nutritional therapies may modify genes, i.e.,
that genes are not ﬁxed. The convoluted term “nutritional supple-
ment pill ingredients” is similarly contradictory, “nutritional” and
“ingredients” often associated with food, i.e., consumer culture,
“supplements” with lifestyle or wellness products and “pills” with
medicine, but in a colloquial sense. This statement illustrates how
the intermediate frame frequently mixed lifestyle and medical
frames, producing intentionally and sometimes clumsily confusing
deﬁnitions and statements.
Some nutrigenetic testing companies (particularly Genetic
Health, Genovations and Interleukin Genetics) framed their
services as akin to medicine, also spelling out the catchwords
disease and prediction.
Our predictive genomic proﬁles assess genetic variations in each
person that, when combined with modiﬁable factors in the
environment, may increase disease risk. This empowers physi-
cians and patients to realize:
 Earlier, more effective preventive interventions-years before
disease develops;
 Precise, customized therapies that truly address each individ-
ual’s needs;
 Improved clinical insight into patients with treatment-resis-
tant “chronic” conditions (Genovations, 2008, introductory
page).
In this paragraph, Genovations indicated it assessed “disease
risk,” which could signal to regulators that it was selling medical
devices. It also used clinical words, such as physicians, patients,
interventions, treatments and chronic conditions, throughout the
text. Even if the statement did not say much concrete about the
company’s tests or treatments, the ubiquitous clinical vocabulary
framed the services as serious or more like “medicine” rather than
consumer culture.
The three frames (lifestyle, intermediate and medicine) were
also created through the use of visuals and colours. In 2007, Sciona’s
frontpage featured three images on white background: one of
a youngish smiling couple, against a green, leafy background, one ofgleaming sweet peppers and one of a scientist in white suit and
goggles peering into a microscope. These stock photographs sought
to associate Sciona with lifestyle (the couple, the peppers) and
science. Salugen’s frontpage in 2008 featured a large photograph of
an extended family, sitting on a shore in informal summer-clothes.
The image showed their bodies from the neck down (as if to protect
anonymity) and next to each person a caption stated, for example,
“predisposed susceptibility to diabetes.” Whilst the clothing of the
people and the setting communicated informality, the captions
created an ominous sense of illnesses passed on in the family. The
frontpage of the UK company Genetic Health had a white back-
ground with light green accents and featured a small image of
a stethoscope on the side and a gleaming lime in the company
banner. Whilst the stethoscope and the airy and rather formal and
professional layout framed the company as “medical,” the image of
the lime and light green softened this frame, communicating life-
style or wellness.
Overall, the nutrigenetic testing companies dissociated them-
selves from clinical genetic tests for genes that “cause” disease.
They were creating new frames or models for genetic tests as either
lifestyle or less-serious medicine or somewhere between the two.
The companies created these categories not only through explicit
statements about not being medicine but consistent framing of
their tests as more informal than medical devices through rhetoric,
images and colour-schemes on their webpages.Between self-health and patients
Another prominent feature of the webpages was the way in
which they addressed their customers as an individual, who should
take personal charge of her/his wellbeing:
Whether you choose to “see” your genes or not, they are always
there. By choosing to look at them, you are giving yourself the
opportunity to do something about them. In this way, you can
more activelydand more accuratelydpromote your health
(Genovations, 2008, consumer page, patient’s guide to
genomics).
This statement depicted the customers of the tests as individuals
who should acquire personalised, genetic information to improve
their health or prevent disease. This depiction reiterated and was
supported by the ubiquitous, contemporary individualist or neo-
liberal preventive public health agendadof which preventive
genomics forms a partdaccording to which individuals should
improve their personal behaviour to prevent common diseases (e.g.
Department of Health, 2001; Harvey, 2009; Rose, 2007).
All companies depicted their customers as active health-
seekers, but they differed in terms of how they conﬁgured the users
of their services and how they delivered those services (see
Woolgar, 1991 on conﬁguring users of technology). Companies
framing their tests as lifestyle (Sciona and its distributors Genelex
and Market America) all sold their tests online, although Sciona
also offered them through varied intermediaries. Sciona conﬁgured
its customers as making sense of their health using a graph,
combining results from the genetic test panel and lifestyle
questionnaire:
For each of the health categories, your current position on the
MyCellf Position Map-identiﬁed by the icon “You Are Here”-is
plotted by the combination of your Gene Assessment (which
cannot change) and your current Diet and Lifestyle Assessment
(which can change by following the recommendations sug-
gested in your personalized report). Your optimal health goal is
identiﬁed by the “Your Goal” icon (Sciona, 2007, action plan
samples).
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displayed on thewebpage constructed health/illness not as “lesions
in the body” but as informational simulation (see Nettleton, 2004).
The user of the Sciona’s services was, thus, conﬁgured as acquiring
personalized, virtual information about his/her health online and
modifying his/her behaviour according to the simulation on their
own. This stands in stark contrast with the traditional doctor-
patient relationship, based on the former’s expert look and touch in
“a clinic.”
The webpages, dotted with sections such as details on products
and payment methods, also conﬁgured the purchaser of the genetic
test as any online shopper. At its barest, this normalcy was evoked
by Market America’s catalogue, which displayed a simple cut-out
image of the nutrigenetic test kit package together with the price
and “add to cart” icon, indicating it was like any consumer product
sold on the portal.
The companies framing their products as in-between medicine
and consumer culture (“intermediate”), such as Suracell, Salugen
and Nutrigen, framed their customers vis a vis their services slightly
differently. They emphasized that they offered the tests in quasi-
medical settings, such as spas and wellness centers, aided by
professionals of more or less ambiguous qualiﬁcations, such as
“registered nutritionists” (Nutrigen) or trained lifestyle or aging
“coaches” (Suracell):
Why is the Suracell Personal Genetic Health Program offered
through Medispas, Physician’s Ofﬁces, and Wellness Centers?
These types of facilities are best able to provide a favorable
atmosphere for genetic health through recommending stress
reduction, proper diet and exercise. Personnel at these facilities
often have strong backgrounds in agemanagement, and Suracell
provides them with training in the science of Personal Genetic
Health (Suracell, 2008, frequently asked questions).
The references to spas, wellness, stress reduction and favorable
atmosphere conﬁgured the customer as being served in a pleasur-
able setting or being “pampered.” The attention provided for the
customer was depicted as professional but not medical with
references to expertise, training and background in stress reduction
and age management. Yet, Suracell, Nutrigen and Salugen all at
some point between 2006 and 2007 sold their tests direct online.
So, the references to relaxation and anti-aging also conﬁgured the
customer as purchasing online products associatedwith beauty and
health rather than medicine. This notionwas reinforced by images,
such as Salugen’s large depiction of a young, nude woman
immersed in water (on its SpaGen page), symbolizing rejuvenation
and sensuality and frequently employed in advertising for personal
hygiene and cosmetic products.
Companies framing their tests as predicting disease risk
(Genetic Health, Genovations) indicated on their webpages that
their tests were available through a physician. For example:
Preventive genetic diagnostics helps to explain why individuals
are affected differently by the same environmental factors. Most
importantly, it enables the physician to select suitable measures
for his patient tailored to his individual genetic needs (Genetic
Health, 2008, doctors’ area).
In this description, users were conﬁgured as “patients” in
a traditional doctor-patient relationship, where the expert makes
the decisions in a paternalistic fashion, such as “selects suitable
measures.” The users were also addressed indirectly, as the pages
were formally addressed to physicians (“doctors area”) communi-
cating that the company was selling the tests to healthcare
professionals. The expectation of a clinical relationship was
supported by images of stethoscopes (Genetic Health) or ofa middle-aged, male doctor reading notes (Nutrigen). Regardless of
these depictions, Genetic Health offered its nutrigenetic tests direct
online. On its webpage, the company noted it can “email [the test-]
report directly to you” but “recommended” that “one of our doctors
go through it with you,” “on the telephone” or in “our clinic”
(Genetic Health, 2007, DNA testing services). Genetic Health, thus,
did not necessarily conﬁgure its customer as a patient in a clinic but
as someone purchasing a medical-like service online but backed up
with clinical support, if required, via phone or face-to-face.
The online sale of nutrigenetic tests was often raised in regu-
latory discussions. Nevertheless, even if proclamations were made
about the need for professional guidance, the recommendations
frequently veered towards regulation of information provided to
the consumers (e.g. Gutman, 2006), suggesting a consumer regu-
lation rather than a medical one. The UK Human Genetics
Commission had made a rather woolly recommendation that
“speciﬁc tests” should be offered through “speciﬁc outlets” (HGC,
2007: 3), indicating that the delivery of genetic tests should be
arranged, seemingly on a sliding scale, based on the nature of the
tests. In this situation, the companies were tallying the way they
framed their tests with how they delivered them. So, companies
that framed their services as lifestyle, delivered their tests direct
online and companies that had framed their tests as medicine
indicated on their webpages that their customers would receive, in
some form, advice from a physician.
Similar industry self-regulation has been observed by Fox et al.
(2005), who discovered that drugs, such as Viagra and Orlistat (for
weight loss), which were considered “lifestyle” were sold in UK
online pharmacies. Fox et al. (2005) did not explore how certain
drugs became deﬁned as “lifestyle,” as we have done. Yet, their
research suggests that pharmaceutical and consumer indus-
trydresponding to regulatory pressures and seeking to create
a marketdwere strategically creating a new category of “less
serious” or lifestyle products between medicine and consumer
culture, which could be sold in more liberal ways. The sale of
nutrigenetic tests in conjunction with computer-generated, “per-
sonalised” graphs, in spas, and with phone consultation with
a physician illustratedwhat the liberal ways of deliverymightmean
in the future, not only in relation to genetic tests but “lifestyle”
services more broadly.
Food, formulas and drugs
An important component of the nutrigenetic testing companies’
marketing were descriptions of the advice or treatment offered
based on the genetic test. The companies’ proﬁles also differed in
this respect.
Sciona, in particular, focused on offering advice on diet and
foods:
First, make your choices from a variety of whole foods each day,
preferably organic whole foods. Click here to read What about
whole foods? Whole foods retain all their original nutrients, in
the correct proportions intended by Mother Nature (Sciona,
2008, Healthy Living pages).
In this statement, Sciona emphasized the “naturalness” (with
references to organic foods and Mother Nature) of the treatments it
offered. This description accomplished two things. First, it mobi-
lized the ubiquitous marketing discourse for things “natural” that
frequently evoke notions of wholesome past and non-Western
cultures to sell varied products from perfume to fair-trade coffee
beans (on the colonialist underpinnings of such marketing see
Stacey, 2000). In relation to health, the naturalness of foods also
gains its meaning from its opposition to “artiﬁcial” drugs, and
people have been found to prefer natural remedies, such as
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ered potentially dangerous, habit-forming and “unnatural” (e.g.
Nichter & Thompson, 2006). Second, by offering healthy eating
advice on the back of the nutrigenetic tests Sciona circumvented
accusations of giving medical advice and appeared offering advice
that was harmless. Indeed, in its report on DTC genetic testing
Human Genetics Commission noted that the nutrigenetic tests and
advice were “fairly innocuous” (HGC, 2007: 3).
However, the innocuousness of the advice also became a target
of criticism. In the GAO report, nutrigenetic testing companies were
accused of offering “common sense” advice, such as recommending
eating vegetables, as allegedly genotype-speciﬁc (GAO, 2006). This
critique accused nutrigenetic testing companies of giving advice
that was too general, failing to meet the traditional expectations of
medicine to identify a single cause and fetch a “silver bullet”
treatment to target it, as in bacteria/antibiotics. Many nutrigenetic
companies, particularly those framing their products as between
medicine and lifestyle or “intermediate” (Nutrigen, Suracell, Salu-
gen), but also others (Genelex, Market America, Interleukin
Genetics) had solved the problem of providing treatments that
were too general or too medical by offering various supplements or
“formulas,” purportedly beﬁtting a speciﬁc genotype. Interleukin
Genetics’s description of its patented “CardioEA” formula illus-
trated the typical contents of such formulas:
The doctor recommended 81 mg dose of Aspirin with the
combination of Vitamins B6, B12, Folic Acid, L-Arginine and
Aged Garlic Extract” for “heart health” (Interleukin Genetics,
2008, Innovations).
These formulas constituted quasi-medicines e often containing
vitamins, plant extracts and compounds possibly having health
beneﬁts e between food items and drugs. The way in which the
formulas were described and concocted also strategically associ-
ated them with “natural” remedies, such as garlic and other plant
compounds, and medicine, such as Aspirin.
Still, a few nutrigenetic testing companies indicated on their
webpages that they would provide advice about “medical”
treatments:
The knowledge of the personal genomic constellation of
a patient helps the physician to select suitable primary
preventive therapeutic measures as well as to plan individual
medication in order to avoid or reduce speciﬁc risks of devel-
oping CVD [cardiovascular disease] (Genetic Health, 2007,
doctors’ area).
Here Genetic Health, referring to medications, indicated that its
physicians would provide advice about pharmaceuticals in associ-
ation with the genetic test. In so doing, the company represented
itself as providing “proper” or serious and speciﬁc interventions,
rather than general dietary advice or ambiguous quasi-medicines.
At the same time, it also made the company liable to accusations of
“unnecessarily” medicalising people in light of the questionable
validity of the tests, which has been raised by genomic researchers
(Melzer & Zimmern, 2002) and regulators (HGC, 2003). The choice
of “treatments” foregrounded the general dilemma facing the
companies of whether to offer potent but potentially serious/
harmful products or ambiguous but harmless ones.
The regulatory initiatives focused on the nutrigenetic testing
technology and treatments and advice were only referred to in
terms of the potentially harmful “effects” of the tests (HGC, 2007:
2). There already existed special regulation for products offered by
the nutrigenetic testing companies, such as supplements and
nutraceuticals. The Dietary Supplement and Health Education Act
of 1994 had forbidden manufacturers to make claims about “healthand disease” but it did not require them to strictly “prove” their
claims (Nichter & Thompson, 2006). The case of functional foods,
such as cholesterol lowering spreads, had been slightly different in
that FDA had required the manufacturers to submit evidence for
their claims but had allowed them to claim a health or disease
beneﬁt (Lehenkari, 2003). This regulation where vague claims
provoke less stringent regulation and vice versa parallels theway in
which nutrigenetic testing companies were pitching their products
and services slightly differently. As nutrigenetic companies had
close connections with the nutrition and consumer industries, it is
conceivable that they had used the marketing and regulation of
nutritional products as a model in designing a strategy for the
genetic tests. The novelty of nutrigenetics was that it encompassed
an entire family of liminal products from diagnostic tests to
matching treatments, perhaps giving a preview of how the
commercial health risk identiﬁcation and prevention market will
develop in the future.
Conclusion
The little research published on nutrigenetic testing so far has
focused on the poor quality of information on the companies’
webpages (e.g. Geransar & Einsiedel, 2008; Stirling, 2008), although
it has also been suggested that the ﬁeld resonates with the
contemporary, individualist preventive health agenda (Harvey,
2009). Others have looked for ways to regulate nutrigenetic
testing, suggesting differential categories for “consumer and life-
style” and “predispositional” testing (Martin & Frost, 2003) or
arguing against the notion of lifestyle genetics (Melzer et al., 2008).
We have not evaluated the webpages against a standard or
reﬂected on how the information and products offered by nutri-
genetic testing companies should be regulated. Rather, we have
examined how these scholarly, regulatory and popular discussions
were creating a new social space for products between medicine
and consumer culture, which was unraveling on the companies’
websites.
The existence of markets for consumer goods with healing
qualities is, obviously, not new (see Tomes, 2001). What we claim is
new, or at least this development has become much more intense,
is that medical/research, policy and industry communities are
creating a new regulated space for such liminal products. The
historical speciﬁcity of the development is highlighted by Gieryn’s
(1983, 1999) research on boundary work. The genomics researchers
and policy makers in public, scholarly and regulatory forums
appeared to be performing boundary work (Gieryn,1983,1999), i.e.,
to delegitimize the tests as outside of proper medicine and science.
Yet, distinctly different from Gieryn’s historical cases, the
commentaries ended up creating a new marketing and regulatory
space for the tests between medicine and consumer culture, which
legitimated them, even if in different terms.
Sociologists have argued that contemporary medicine and
science are losing their 20th century autonomy and become infused
with commercial, government and lay interests. This has been
described by terms such as biomedicalisation (Clarke et al., 2003) or
mode 2 science (Nowotny et al., 2001). We contend that the
emergence of categories of products between medicine and
consumer culture is one of the mechanisms through which the
boundaries of medicine/science blur.
Social scientists have noticed the emergence of “lifestyle”
products, such as commercial genetic tests and drugs (e.g. Edgley,
2007; Fishman, 2004; Fox et al., 2005; Geransar & Einsiedel,
2008). Yet, they have not studied how these products became
deﬁned this way. There is also scattered research that discusses the
creation of new self-(regulatory) categories for online pharmacies
(Fox et al., 2005), dietary supplements (Nichter & Thompson, 2006),
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terol lowering statins (Edgley, 2007). This research suggests a surge
of products with an ambiguous status vis a vis medical and
consumer goods. Our article is taking this emergent research area
forward by analyzing the regulatory and marketing processes that
seek to create an identity and open up a social space for these
products.
We have argued that the regulation of nutrigenetic tests was
ambiguous part because the novel tests fell between the cracks of
existing regulation. But the contradictory comments and recom-
mendations made by genomics researchers and policy makers
about the tests was also inﬂuenced by the fact that they shared the
companies’ interest in promoting genomic applications and the
contemporary individualist self-health agenda. This illustrates how
the new regulation was facilitated by the speciﬁc interests of
genomics research and policy community and the broader indi-
vidualist or neo-liberal zeitgeist, which forged the commercial,
government and scientiﬁc agendas behind the new category.
We have pinpointed how the companies mirrored and negoti-
ated the regulatory positions by associating their services with
health, medicine and science but framing them (Goffman, 1974/
1986) as more “informal” than medical products. Such framing
was consistently applied through rhetoric, visuals, colours, ways in
which consumers were invited to imagine themselves, how the
tests were delivered and what kinds of products were offered in
association with the tests and how those products were described.
Companies had slightly different strategies in this respect, pitching
their products as lifestyle or less-serious medicine (see Table 2).
Such stratiﬁed categories suggest possible shapes that the market
between medicine and consumer culture may take. The nutrige-
netic testing market also clearly borrowed ideas from and collab-
orated with related industry, such as the supplements industry. In
addition, the practices created by the more medically oriented
companies, such as offering phone consultations with physicians,
were similar to those of companies marketing genetic tests for
predisposition to disease, such as DNAdirect.
In this new area, many questions remain. For example, whilst
nutrigenetic expands biomedical jurisdiction into eating, it also
operates in reverse, rendering a rareﬁed medical tech-
nologydgenetic testingdconsumer culture. Whilst (bio)medical-
isation has been extensively studied, consumerization, i.e.,
rendering a medical technology consumer culture has rarely been
investigated. It raises the question of, for example, whether and
how does the meaning of genetic testing change for the consumer
when it is sold adjacent to garden furniture online. How people
understand and use lifestyle technologies clearly begs further
research.
Furthermore, in 2009 Sciona and its distributors ceased selling
nutrigenetic tests. This could be due to the drying of investment
funds amidst global economic downturn or competition from new
companies, such as 23andMe and deCODEme, selling whole
genome scans. It is unclear if nutrigenetic testing as a business
concept will survive, even if commercial genetic testing seems here
to stay. We have here argued that the emergent categories between
medicine and consumer culture, so well illustrated by nutrigenetic
tests, are a broad phenomena, not limited to genetic testing. How
the lifestyle market develops and perhaps consolidates into some
consistent regulatory andmarketing frameworks also calls formore
research.Appendix. Supplementary material
Supplementary material associated with this article can be
found, in theonline version, at doi:10.1016/j.socscimed.2009.10.066.References
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